Neuroendocrine Tumor Market Insights, Epidemiology and Market Forecast 2030

March 16 10:42 2020
Neuroendocrine Tumor Market Insights, Epidemiology and Market Forecast 2030
Neuroendocrine tumors (NETs) are a complex group of tumors that develop predominantly in the digestive or respiratory tracts but can occur in many areas of the body.

Albany, US – DelveInsight launched its new report on Neuroendocrine Tumor Market Insights, Epidemiology and Market Forecast 2030

DelveInsight’s “Neuroendocrine Tumors – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Neuroendocrine Tumors, historical and forecasted epidemiology as well as the Neuroendocrine Tumors market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some key facts of the report:
1. The total prevalence of NETS was estimated at approximately 453,191 in 2017, for 7MM.
2. Among the European countries, Germany had the highest prevalent population of Neuroendocrine Tumors with approximately    49,690 cases, followed by France, which had a prevalent adult population of approximately 40,328 in 2017. On the other hand, Spain had the lowest adult prevalent population of approximately 27,853 cases in 2017.

Key benefits of the report:
1. The report covers the descriptive overview of Neuroendocrine Tumors, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies.
2. Comprehensive insight has been provided into the Neuroendocrine Tumors epidemiology and treatment in the 7MM.
3. Additionally, an all-inclusive account of both the current and emerging therapies for Neuroendocrine Tumors are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
4. A detailed review of Neuroendocrine Tumors market; historical and forecasted is included in the report, covering drug outreach in the 7MM.

Request for sample pages:

“Around 70% of NET patients are functional, and 30% cases non-functional.”

Neuroendocrine tumors (NETs) are a complex group of tumors that develop predominantly in the digestive or respiratory tracts but can occur in many areas of the body. These tumors arise from cells called neuroendocrine cells. Like all cancers, NETs develop when the specialized cells undergo changes causing them to divide uncontrollably and grow into an abnormal tissue mass (tumour).     

Key pharma companies involved:
1. Progenics Pharmaceuticals
2. Hutchison MediPharma
3. Pfizer
4. EpicentRx
5. Ignyta
6. Amgen
7. Antengene
8. Mateon Therapeutics

Drugs involved:
1. Azedra
2. Sulfatinib
3. Axitinib
4. Entrectinib
5. AMG-479
6. Carfilzomib
7. Fosbretabulin
8. RRx-001
9. ATG-008

Request for a free sample report:

Table of Contents:

1. Key Insights
2. Neuroendocrine Tumor Epidemiology Overview at a Glance
3. Neuroendocrine Tumor Disease Background and Overview
4. Neuroendocrine Tumor Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Total Neuroendocrine Tumor Prevalent Patient Population
4.3. Total Incident Patient Population of Neuroendocrine Tumor
4.4. Country Wise Neuroendocrine Tumor Epidemiology
4.5. United States
4.6. EU5 Countries
4.7. Germany
4.8. France
4.9. Italy
4.10. Spain
4.11. United Kingdom
4.12. Japan
5. Neuroendocrine Tumor Treatment Algorithm
6. Unmet needs
7. Neuroendocrine Tumor Marketed drugs
8. Neuroendocrine Tumor Emerging drugs
9. Key Cross Competition
9.1. Iobenguane I-131: Progenics Pharmaceuticals
9.2. 177Lu-edotreotide PRRT: ITM Isotopen Technologien Muenchen
9.3. AMG 479: Amgen
9.4. Anlotinib: Advenchen Laboratories
9.5. Carfilzomib: Amgen
9.6. ATG-008: Antengene
9.7. Entrectinib: Ignyta
9.8. Fosbretabulin: Mateon Therapeutics
9.9. Ipilimumab: Bristol-Myers Squibb
9.10. Ribociclib: Novartis
9.11. Pembrolizumab: Merck
9.12. RRx-001: EpicentRx
9.13. Axitinib: Pfizer
9.14. Cabozantinib: Exelixis
9.15. CAM2029: Camurus
9.16. Atezolizumab and Bevacizumab: Genentech
9.17. Lenvatinib: Eisai
9.18. Pasireotide LAR: Novartis
9.19. Spartalizumab: Novartis
9.20. Tirapazamine: Teclison
9.21. Pentarin: Tarveda Therapeutics
9.22. Sulfatinib: Hutchison MediPharma
9.23. Ibrutinib: Pharmacyclics
9.24. Ramucirumab: Eli Lilly
9.25. ALT 803: Altor Biosciences
9.26. Talimogene laherparepvec: Amgen
9.27. Netazepide: Trio Medicines
10. Neuroendocrine Tumor 7 Major Market analysis
10.1. Key Findings
10.2. Neuroendocrine Tumor Market Size in 7MM
10.3. Neuroendocrine Tumor Market Outlook by Country
10.4. The United States: Market Outlook
10.5. EU-5 Countries: Market Outlook
10.6. Germany
10.7. France
10.8. United Kingdom
10.9. Spain
10.10. Italy
10.11. Japan: Market Outlook
11. Market Drivers
12. Market Barriers
13. Appendix
14. DelveInsight Capabilities
15. Disclaimer
16. About DelveInsight

Related Reports:

Neuroendocrine Tumors (NETs) – Epidemiology Forecast to 2030

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NEVADA 89107
Country: United States